Patient-reported outcomes from IMvigor130: a global, randomised, partially blinded Phase III study of atezolizumab + platinum-based chemotherapy vs placebo + platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
This presentation reports patient-reported outcomes data from IMvigor130, a global Phase III, multicentre, randomised, placebo-controlled trial evaluating atezolizumab ± platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. Here, EORTC QLQ-30 data are presented to further evaluate the overall treatment benefit of adding atezolizumab to platinum-based chemotherapy.